Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Joshua J. McFarlane; Mark D. Kochenderfer; Mark R. Olsen; Todd M. Bauer; Ana Molina; Ralph J. Hauke; James A. Reeves; Sunil Babu; Peter Van Veldhuizen; Bradley Somer; Vijay Gunuganti; Ian Schnadig; Saby George; Ray D. Page; Edward Arrowsmith; Rohit K. Jain; Joshua Zhang; M. Brent McHenry; Jennifer L. Johansen; Nicholas J. Vogelzang

doi:10.1016/J.CLGC.2020.05.006

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Joshua J. McFarlane
, Mark D. Kochenderfer
, Mark R. Olsen
, Todd M. Bauer
, Ana Molina
, Ralph J. Hauke
, James A. Reeves
, Sunil Babu
, Peter Van Veldhuizen
, Bradley Somer
, Vijay Gunuganti
, Ian Schnadig
, Saby George
, Ray D. Page
, Edward Arrowsmith
, Rohit K. Jain
, Joshua Zhang
, M. Brent McHenry
, Jennifer L. Johansen
, Nicholas J. Vogelzang

Hematology/Oncology, Virginia Cancer Institute, Richmond, VA
Hematology and Medical Oncology, Blue Ridge Cancer Care, Roanoke, VA.
Medical Oncology, Oklahoma Cancer Specialists, Tulsa, OK.
Sarah Cannon Research Institute
Cornell University
Nebraska Cancer Specialists, Omaha, NE.
Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN.
Research Medical Center
Medical Oncology, The West Clinic, Memphis, TN.
University of Texas at San Antonio
Compass Oncology, Tigard, OR.
Roswell Park Cancer Institute
The Center for Cancer and Blood Disorders, Fort Worth, TX.
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL.
Bristol-Myers Squibb
US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Genitourinary Cancer
Volume	18
Issue number	6
DOIs	https://doi.org/10.1016/J.CLGC.2020.05.006
State	Published - Dec 1 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1016/J.CLGC.2020.05.006License: Unspecified

Cite this

McFarlane, J. J., Kochenderfer, M. D., Olsen, M. R., Bauer, T. M., Molina, A., Hauke, R. J., Reeves, J. A., Babu, S., Van Veldhuizen, P., Somer, B., Gunuganti, V., Schnadig, I., George, S., Page, R. D., Arrowsmith, E., Jain, R. K., Zhang, J., McHenry, M. B., Johansen, J. L., & Vogelzang, N. J. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer, 18(6). https://doi.org/10.1016/J.CLGC.2020.05.006

McFarlane, JJ, Kochenderfer, MD, Olsen, MR, Bauer, TM, Molina, A, Hauke, RJ, Reeves, JA, Babu, S, Van Veldhuizen, P, Somer, B, Gunuganti, V, Schnadig, I, George, S, Page, RD, Arrowsmith, E, Jain, RK, Zhang, J, McHenry, MB, Johansen, JL & Vogelzang, NJ 2020, 'Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.', Clinical Genitourinary Cancer, vol. 18, no. 6. https://doi.org/10.1016/J.CLGC.2020.05.006

@article{605832d17ad54c5e920c741d9f8aac3c,

title = "Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.",

author = "McFarlane, \{Joshua J.\} and Kochenderfer, \{Mark D.\} and Olsen, \{Mark R.\} and Bauer, \{Todd M.\} and Ana Molina and Hauke, \{Ralph J.\} and Reeves, \{James A.\} and Sunil Babu and \{Van Veldhuizen\}, Peter and Bradley Somer and Vijay Gunuganti and Ian Schnadig and Saby George and Page, \{Ray D.\} and Edward Arrowsmith and Jain, \{Rohit K.\} and Joshua Zhang and McHenry, \{M. Brent\} and Johansen, \{Jennifer L.\} and Vogelzang, \{Nicholas J.\}",

note = "{\textcopyright} 2020 The Authors Background: The open-label phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma. Three cohorts included patients with predominantly clear cell histology, non-clear cell histologies, or brain metastases.",

year = "2020",

month = dec,

day = "1",

doi = "10.1016/J.CLGC.2020.05.006",

language = "American English",

volume = "18",

journal = "Clinical Genitourinary Cancer",

number = "6",

}

TY - JOUR

T1 - Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

AU - McFarlane, Joshua J.

AU - Kochenderfer, Mark D.

AU - Olsen, Mark R.

AU - Bauer, Todd M.

AU - Molina, Ana

AU - Hauke, Ralph J.

AU - Reeves, James A.

AU - Babu, Sunil

AU - Van Veldhuizen, Peter

AU - Somer, Bradley

AU - Gunuganti, Vijay

AU - Schnadig, Ian

AU - George, Saby

AU - Page, Ray D.

AU - Arrowsmith, Edward

AU - Jain, Rohit K.

AU - Zhang, Joshua

AU - McHenry, M. Brent

AU - Johansen, Jennifer L.

AU - Vogelzang, Nicholas J.

N1 - © 2020 The Authors Background: The open-label phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma. Three cohorts included patients with predominantly clear cell histology, non-clear cell histologies, or brain metastases.

PY - 2020/12/1

Y1 - 2020/12/1

UR - https://institutionalrepository.aah.org/alghintmedfaculty/1/

U2 - 10.1016/J.CLGC.2020.05.006

DO - 10.1016/J.CLGC.2020.05.006

M3 - Article

VL - 18

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 6

ER -

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Disciplines

Access to Document

Other files and links

Cite this